# ORIC Pharmaceuticals
 (stock symbol: ORIC) Logo in transparent PNG and SVG formats

## ORIC Pharmaceuticals
 Logo large

### ORIC Pharmaceuticals
 Logo large Download PNG (13.54 KB)

![ORIC Pharmaceuticals
 Logo large Download PNG (13.54 KB)](/img/orig/ORIC_BIG-bfd4ca41.png)

### ORIC Pharmaceuticals
 Logo large Download SVG (2.46 KB)

![ORIC Pharmaceuticals
 Logo large Download SVG (2.46 KB)](/img/orig/ORIC_BIG-b935fbc2.svg)

## ORIC Pharmaceuticals
 Logo icon format

### ORIC Pharmaceuticals
 Logo icon format Download PNG (49 KB)

![ORIC Pharmaceuticals
 Logo icon format Download PNG (49 KB)](/img/orig/ORIC-5272991a.png)

### ORIC Pharmaceuticals
 Logo icon format Download SVG (1.39 KB)

![ORIC Pharmaceuticals
 Logo icon format Download SVG (1.39 KB)](/img/orig/ORIC-ee808d05.svg)

## ORIC Pharmaceuticals
 Logo large for dark backgrounds

### ORIC Pharmaceuticals
 Logo large for dark backgrounds Download PNG (29.72 KB)

![ORIC Pharmaceuticals
 Logo large for dark backgrounds Download PNG (29.72 KB)](/img/orig/ORIC_BIG.D-aa5650ef.png)

### ORIC Pharmaceuticals
 Logo large for dark backgrounds Download SVG (2.46 KB)

![ORIC Pharmaceuticals
 Logo large for dark backgrounds Download SVG (2.46 KB)](/img/orig/ORIC_BIG.D-1c1a0818.svg)

## ORIC Pharmaceuticals
 Logo icon format for dark backgrounds

### ORIC Pharmaceuticals
 Logo icon format for dark backgrounds Download PNG (48.6 KB)

![ORIC Pharmaceuticals
 Logo icon format for dark backgrounds Download PNG (48.6 KB)](/img/orig/ORIC.D-73a41dc7.png)

### ORIC Pharmaceuticals
 Logo icon format for dark backgrounds Download SVG (1.39 KB)

![ORIC Pharmaceuticals
 Logo icon format for dark backgrounds Download SVG (1.39 KB)](/img/orig/ORIC.D-fecb0b6c.svg)

## About ORIC Pharmaceuticals


ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

1. Website domain: oricpharma.com
2. Employees: 83
3. Marketcap: $0.23 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
